Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro

Gene

Volumn 550, Issue 1, 2014, Pages 110-116

  Awasthy, Disha ^a,b   Ambady, Anisha ^a,c   Narayana, Ashwini ^a   Morayya, Sapna ^a,c   Sharma, Umender ^a,d  

^a ASTRAZENECA   (United Kingdom)

^b Biocon Bristol Myer squib R and D Centre   (India)

^c Strand Life Sciences Pvt Ltd ^*  (India)

^d GangaGen Biotechnologies Pvt Ltd   (India)

Author keywords

Essential; Gene knockout; M. tuberculosis; NADH dehydrogenase; Ndh; NdhA

Indexed keywords

PHENOTHIAZINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; BACTERIAL PROTEIN; ISOENZYME; NADH DEHYDROGENASE II;

ARTICLE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENE INACTIVATION; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL VIABILITY;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

BACTERIAL PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKOUT TECHNIQUES; ISOENZYMES; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; NADH DEHYDROGENASE; PHENOTHIAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84906935494     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.08.024     Document Type: Article

References (32)

1. Abubakar I., Zignol M., Falzon D., Raviglione M., Ditiu L., et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 2013, 13:529-539.
2. Andries K., Verhasselt P., Guillemont J., Göhlmann H.W., Neefs J.M. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
3. Awasthy D., Ambady A., Bhat J., Sheikh G., Ravishankar S., et al. Essentiality and functional analysis of type I and type III pantothenate kinases of Mycobacterium tuberculosis. Microbiology 2010, 156:2691-2701.
4. Bald D., Koul A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets?. FEMS Microbiol. Lett. 2010, 308:1-7.
5. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009, 7:845-855.
6. Boonaiam S., Chaiprasert A., Prammananan T., Leechawengwongs M. Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. Clin. Microbiol. Infect. 2010, 16:396-399.
7. Cardoso R.F., Cardoso M.A., Leite C.Q., Sato D.N., Mamizuka E.M., et al. Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil. Mem. Inst. Oswaldo Cruz 2007, 102:59-61.
8. Cook G.M., Berney M., Gebhard S., Heinemann M., Cox R.A., et al. Physiology of mycobacteria. Adv. Microb. Physiol. 2009, 55:81-182.
9. Fattorini L., Piccaro G., Mustazzolu A., Giannoni F. Targeting dormant bacilli to fight tuberculosis. Mediterr. J. Hematol. Infect. Dis. 2013, 5:e2013072.
10. Fisher N., Warman A.J., Ward S.A., Biagini G.A. Chapter 17 type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays. Methods Enzymol. 2009, 456:303-320.
11. Hazbón M.H., Brimacombe M., Bobadilla del Valle M., Cavatore M., Guerrero M.I., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2006, 50:2640-2649.
12. Hurdle J.G., O'Neill A.J., Chopra I., Lee R.E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 2011, 9:62-75.
13. Kaur P., Agarwal S., Datta S. Delineating bacteriostatic and bactericidal targets in mycobacteria using IPTG inducible antisense expression. PLoS One 2009, 4(6):e5923.
14. Koul A., Vranckx L., Dendouga N., Balemans W., Van den Wyngaert I., et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 2008, 283:25273-25280.
15. Lee A.S., Teo A.S., Wong S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2001, 45:2157-2159.
16. Mesfin Y.M., Hailemariam D., Biadglign S., Kibret K.T. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One 2014, 9:e82235.
17. Miesel L., Weisbrod T.R., Marcinkeviciene J.A., Bittman R., Jacobs W.R. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 1998, 180:2459-2467.
18. Miller J.L., Velmurugan K., Cowan M.J., Briken V. The type I NADH dehydrogenase of Mycobacterium tuberculosis counters phagosomal NOX2 activity to inhibit TNF-alpha-mediated host cell apoptosis. PLoS Pathog. 2010, 6:e1000864.
19. Mogi T., Matsushita K., Murase Y., Kawahara K., Miyoshi H. Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II). FEMS Microbiol. Lett. 2009, 291:157-161.
20. Parish T., Stoker N.G. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 2000, 146:1969-1975.
21. 1 ATPase: DNA sequence of the atp operon and characterization of atp mutants. J. Bacteriol. 1994, 176:6802-6811.
22. Saleh A., Friesen J., Baumeister S., Gross U., Bohne W. Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob. Agents Chemother. 2007, 51:1217-1222.
23. Segala E., Sougakoff W., Nevejans-Chauffour A., Jarlier V., et al. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob. Agents Chemother. 2012, 56:2326-2334.
24. Sharma U. Current possibilities and unresolved issues of drug target validation in Mycobacterium tuberculosis. Expert Opin. Drug Discov. 2011, 6:1171-1186.
25. Shirude P., Paul B., Roy Choudhury N., Kedari C., Bandodkar B., et al. Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents. ACS Med. Chem. Lett. 2012, 3:736-740.
26. Teh J.S., Yano T., Rubin H. Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis. Infect. Disord. Drug Targets 2007, 7:169-181.
27. o-ATP synthase of Mycobacterium smegmatis is essential for growth. J. Bacteriol. 2005, 187:5023-5028.
28. + ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob. Agents Chemother. 2005, 49:708-720.
29. Weinstein E.A., Yano T., Li L.S., Avarbock D., Avarbock A., et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4548-4553.
30. Wells C.D., Cegielski J.P., Nelson L.J., Laserson K.F., Holtz T.H., et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 2007, 196:S86-S107. (Suppl.).
31. Xie Z., Siddiqi N., Rubin E.J. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2005, 49:4778-4780.
32. Yano T., Li L.S., Weinstein E., Teh J.S., Rubin H. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 2006, 281:11456-11463.